Skip to main content
Search
Main content
Alzheimer's & dementia : the journal of the Alzheimer's Association
Published

Increased neuroplastic activity in the pathogenesis of Alzheimer's disease

Authors

Corey J Bolton, Panpan Zhang, Sydney R Wilhoite, Elizabeth E Moore, Michelle L Houston, Kimberly R Pechman, Logan Dumitrescu, Amalia Peterson, Omair A Khan, Dandan Liu, Katherine A Gifford, Kaj Blennow, Timothy J Hohman, Henrik Zetterberg, Angela L Jefferson

Abstract

Alzheimers Dement. 2025 Nov;21(11):e70897. doi: 10.1002/alz.70897.

ABSTRACT

INTRODUCTION: We test the hypothesis that high levels of neuroplasticity in the context of Alzheimer's disease (AD) risk factors are involved in AD pathogenesis by investigating interactions between cerebrospinal fluid (CSF) levels of growth-associated protein-43 (GAP-43) and AD risk factors (female sex, cerebrovascular risk, mild cognitive impairment, apolipoprotein E [APOE] ε4 genotype, amyloid positivity) on CSF biomarkers of AD pathology (amyloid beta 42/40[Aβ42/40], phosphorylated tau (p-tau)) and neurodegeneration (tau).

METHODS: Baseline GAP-43 levels in 161 non-demented older adults were related to cross-sectional and longitudinal (mean follow-up = 4 years) CSF biomarkers of AD, adjusting for covariates, with GAP-43 x AD risk factor interaction terms.

RESULTS: Higher GAP-43 was cross-sectionally related to all AD biomarkers (p-values < 0.0001) and predicted longitudinal reductions in Aβ42 (p < 0.0001). Associations were stronger in AD risk groups.

DISCUSSION: We found strong support linking increased levels of neuroplasticity in the context of AD risk factors to the pathological cascade of AD over a 4-year mean follow-up period.

HIGHLIGHTS: Cerebrospinal fluid growth-associated protein-43 (GAP-43) is associated with Alzheimer's disease (AD) biomarkers cross-sectionally and longitudinally. GAP-43 interacts with AD risk factors to predict AD biomarkers. Increased neuroplastic activity may play a role in AD pathogenesis.

PMID:41315049 | DOI:10.1002/alz.70897

UK DRI Authors

Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg